News
-
-
-
-
-
-
-
PRESS RELEASE
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
Sanofi presents new data on ALTUVIIIO and fitusiran at ISTH Congress, showcasing potential first- and best-in-class treatments for hemophilia. Fitusiran NDA under FDA review with PDUFA date of March 28, 2025 -
-
-
PRESS RELEASE
BEACN Closes First Tranche of Non-Brokered Private Placement
BEACN Wizardry & Magic Inc. closes First Tranche of non-brokered private placement, issuing 2,890,578 common shares for gross proceeds up to $520,304.04. Shareholders owning more than 10% participated. Proceeds to be used for sales initiatives, inventory purchases, R&D, and working capital
